| 12.57 0.72 (6.08%) | 07-17 15:48 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 15.84 | 1-year : | 18.51 |
| Resists | First : | 13.56 | Second : | 15.84 |
| Pivot price | 12.39 |
|||
| Supports | First : | 11.38 | Second : | 10.02 |
| MAs | MA(5) : | 11.73 |
MA(20) : | 12.3 |
| MA(100) : | 13.14 |
MA(250) : | 19.65 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 41.2 |
D(3) : | 28 |
| RSI | RSI(14): 51.6 |
|||
| 52-week | High : | 69.97 | Low : | 10.02 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TNXP ] has closed below upper band by 48.5%. Bollinger Bands are 19.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 11.91 - 11.97 | 11.97 - 12.02 |
| Low: | 11.1 - 11.17 | 11.17 - 11.23 |
| Close: | 11.74 - 11.85 | 11.85 - 11.95 |
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical firm primarily operating in the clinical development stage. Its overarching mission involves the discovery, acquisition, advancement, and commercialization of novel therapeutic agents and diagnostic tools, all aimed at combating human illnesses and easing patient discomfort. The company boasts a comprehensive pipeline of potential treatments spanning several key medical fields: immunology, rare conditions, infectious diseases, and central nervous system (CNS) disorders. In the realm of immunology, Tonix is progressing with biologics designed to address organ transplant rejection, various autoimmune diseases, and certain forms of cancer. A prominent candidate here is TNX-1500, a humanized monoclonal antibody targeting CD40-ligand, which is being investigated for its utility in preventing both allograft and xenograft rejection, as well as in treating autoimmune disorders. Its rare disease initiatives include TNX-2900, a specific treatment candidate for Prader-Willi syndrome. The infectious disease segment features a diverse array of programs: TNX-801, a vaccine designed to offer protection against smallpox and monkeypox. TNX-1840 and TNX-1850, which are live virus vaccines based on the company's recombinant pox vaccine (RPV) platform, targeting COVID-19. TNX-3500, a small molecule antiviral drug for the treatment of acute COVID-19. TNX-102 SL, a small molecule medication under investigation for Long COVID, a persistent post-acute COVID-19 condition. Finally, the CNS portfolio encompasses both small molecules and biologics intended to manage pain, neurological conditions, psychiatric ailments, and addiction. Notably, TNX-102 SL is also in mid-Phase 3 development for alleviating fibromyalgia symptoms. Other CNS candidates include TNX-1900, which is being developed to prevent migraine headaches, and TNX-1300, a biologic aimed at treating cocaine intoxication. The company was established in 2007 and maintains its headquarters in Chatham, New Jersey.
Wed, 15 Jul 2026
Tonix Pharmaceuticals Announces Publication in the - GlobeNewswire
Mon, 13 Jul 2026
Precision Trading with Tonix Pharmaceuticals Holding Corp. (TNXP) Risk Zones - Stock Traders Daily
Mon, 13 Jul 2026
Tonix Expands TONMYA Medicare Coverage with New Payer Agreement (TNXP) - Yahoo Finance
Mon, 13 Jul 2026
Tonix Pharmaceuticals (TNXP) Secures Medicare Coverage for Tonmy - GuruFocus
Mon, 13 Jul 2026
Tonix Pharmaceuticals Adds Medicare Part D Coverage for TONMYA, Expands Sales Force - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 16 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 45.7 (%) |
| Shares Short | 3,580 (K) |
| Shares Short P.Month | 2,870 (K) |
| EPS | -14.66 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 15.98 |
| Profit Margin | 0 % |
| Operating Margin | -604 % |
| Return on Assets (ttm) | -42 % |
| Return on Equity (ttm) | -72.4 % |
| Qtrly Rev. Growth | 183.1 % |
| Gross Profit (p.s.) | 0.64 |
| Sales Per Share | 1.1 |
| EBITDA (p.s.) | -9.37 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -126 (M) |
| Levered Free Cash Flow | -77 (M) |
| PE Ratio | -0.85 |
| PEG Ratio | 0 |
| Price to Book value | 0.77 |
| Price to Sales | 11.28 |
| Price to Cash Flow | -1.58 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|